You can now read 10 articles each month for free on

The Boston Globe


Genzyme’s new MS therapy OK’d by European officials

European regulators Tuesday put their stamp of approval on Genzyme’s multiple sclerosis drug Lemtrada, giving the Cambridge biotechnology company a second MS treatment for the overseas market only weeks after its first won approval there.

The move vindicated French drug maker Sanofi SA’s decision to pay $20.1 billion for Genzyme in 2011, a deal that hinged on the potential of Lemtrada, then an experimental therapy.

Loading comments...

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week